CClinicalTrials.gg
RecruitingNCT07109349Updated Jun 2, 2026

tAN for First Responders

An interventional study of Sparrow Link in Mental Fatigue and Mental Stress, sponsored by Spark Biomedical, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Spark Biomedical, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed as an open label, single arm, decentralized clinical study in which first responders will receive transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) via the mastoid and the auriculotemporal nerve (ATN) anterior to the tragus. Participants will be enrolled in the study over the course of eight weeks (56 days).

Participants will respond to daily and weekly questionnaires regarding mood, stress, sleep, energy/fatigue, and burnout. Each week, participants will complete consolidated online questionnaires (intended to last no longer than 15 minutes) comprised of the Perceived Stress Short-Form (PSS-4), Well-Being Index (WHO-5), Mini-Z Burnout (5-item), PROMS Sleep Disturbance (PROMIS-SD), GAD-7 (every 2 weeks), and Perceived Stress (PSS-10; monthly). The PSS-10 will replace the PSS-4 on Days 0, 28, and 56.

No tAN treatment will be delivered during the Baseline Period (days between Study Introduction and Day 0). Participants will complete the weekly set of questionnaires ("Weekly Questionnaires") on Day 0. Participants will be recommended to complete the daily set of questionnaires ("Daily Questionnaires ") on the other days of the Baseline Period.

On Days 1 - 28, participants will self-administer one session of one to two hours of tAN therapy each day. Participants will be recommended to complete the daily tAN session post-shift prior to sleep. Weekly Questionnaires will be completed by participants on Study Days 0, 7, 14, 21, 28, 35, 42, 49, and 56. Participants will be recommended to complete Daily Questionnaires on all other study days, up to Day 28. Daily Questionnaires will not be required to be completed by participants. Daily tAN sessions and Daily Questionnaires will cease after Day 28. Participants will complete a Study Satisfaction Questionnaire with the Weekly Questionnaires on Day 56.

Following Day 56, participants will schedule a Study Exit Interview with the Research Coordinator.

02

Conditions studied

  • Mental Fatigue
  • Mental Stress

Keywords

  • Mental resilience
  • tAN
  • Transcutaneous Auricular Neurostimulation
  • Vagus nerve stimulation
  • Neurostimulation
  • First responders
  • taVNS
  • Police officer
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Participant is currently employed in a first responder position
  2. Age ≥ 18 years
  3. Reliable access to an internet-enabled device to complete required questionnaires
  4. GAD-7 score ≥ 5

Exclusion criteria

Exclusion Criteria:

  1. Participant has a history of epileptic seizures
  2. Participant has a history of neurologic diseases or traumatic brain injury
  3. Participant has presence of devices (e.g., pacemakers, cochlear prostheses or implants, neurostimulators)
  4. Participant has abnormal left ear anatomy or ear infection present
  5. Participant has auditory impairment of the left ear (ruptured eardrum, deafness, tinnitus, etc.)
  6. Participant is currently enrolled in another interventional trial
  7. Women of childbearing potential, not using adequate contraception as per the investigator's judgement
  8. Females who are pregnant or lactating
  9. Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Active tAN

    First responders will self-administer once-daily active tAN sessions for 1-2 hours for 28 days. Participants will complete daily and weekly assessments to evaluate levels of stress, mood, energy/fatigue, sleep quality , and burnout. Daily assessments and tAN sessions will cease after Day 28. Participants will continue to complete weekly assessments until Day 56.

    Device: Sparrow Link

Interventions

  • DeviceSparrow Link

    Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. Participants will self-administer daily active tAN sessions on Days 1 - 28.

    Also known as: Transcutaneous Auricular Neurostimulation

05

What researchers measure

Primary outcomes

  1. GAD-7

    The GAD-7 is a valid and efficient tool for screening for GAD and assessing its severity in clinical practice and research. The questionnaire consists of 7 questions in which participants are asked to rate each item on a 0 (not at all) to 3 (nearly every day). GAD-7 total score for the seven items ranges from 0 to 21 where 0-4 represents minimal anxiety, 5-9 represents mild anxiety, 10-14 represents moderate anxiety and 15-21 represent severe anxiety.

    Time frame: Screening, Day 0, Day 14, Day 28, Day 42, Day 56

Secondary outcomes

  1. Perceived Stress Scale (PSS-4, PSS-10)

    The PSS-4 is a brief version of the Perceived Stress Scale used to assess the degree to which situations in one's life are appraised as stressful. The questionnaire consists of 4 items, with participants rating each on a 0 (never) to 4 (very often) scale. Scores range from 0 to 16, with higher scores indicating greater perceived stress. The PSS-10 consists of 10 items that assess how unpredictable, uncontrollable, and overloaded respondents find their lives. Each item is rated on a 0 (never) to 4 (very often) scale. Total scores range from 0 to 40, with higher scores indicating greater perceived stress. The PSS-10 will replace the PSS-4 on Days 0, 28, and 56.

    Time frame: Weekly throughout enrollment beginning Day 0 through Day 56)

  2. PROMIS Sleep Disturbance

    The PROMIS Sleep Disturbance measure evaluates self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. Participants respond to 8 items rated on a 1 (not at all) to 5 (very much) scale. Raw scores are converted to T-scores with a mean of 50 and a standard deviation of 10, where higher scores indicate greater sleep disturbance. The tool is suitable for use in clinical and research populations.

    Time frame: Weekly throughout enrollment beginning Day 0 through Day 56)

  3. WHO-5 Well-Being Index

    The WHO-5 is a short, validated measure of current mental well-being. The questionnaire consists of 5 positively worded items rated on a 0 (at no time) to 5 (all of the time) scale. The raw score ranges from 0 to 25 and is multiplied by 4 to yield a final score from 0 to 100, with higher scores indicating greater well-being. A score below 50 suggests reduced well-being and may indicate the need for further assessment.

    Time frame: Weekly throughout enrollment beginning Day 0 through Day 56)

  4. Mini-Z Burnout Survey

    The Mini-Z Burnout Survey is a brief tool for assessing burnout and job satisfaction. It includes 10 items covering emotional exhaustion, stress, satisfaction, and workload. Most items are rated on a 1 to 5 Likert scale. Higher scores on the burnout item (typically scored 1 to 5) reflect greater burnout, with a score of 3 or higher suggesting at least some level of burnout.

    Time frame: Weekly throughout enrollment beginning Day 0 through Day 56)

06

Study locations

1 of 1 sites recruiting
07

Registry details

Key details

Study ID
NCT07109349
Lead sponsor
Spark Biomedical, Inc.
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Sep 10, 2025
Primary completion
Jul 10, 2026 (estimated)
Completion
Jul 20, 2026 (estimated)
Last update
Jun 2, 2026

Study contacts

Kimi Harada
Contact
clinicaltrials@sparkbiomedical.com
210-404-4162
Navid Khodaparast, PhD
principal investigator · Spark Biomedical, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion